@trh
Pretty stoked about this, I’m not gonna lie.
And this is only half of the disruption: Once treatments are designed for individuals based on known physiological interactions, the monolithic pharmaceutical research and manufacturing (and approval) apparatus is dismantled, or at least rearranged.
Who is on the other side of this innovation, using AI to accelerate approvals, etc.?
Economically, the only way the current machine makes any sense is to provide medication’s that safe safely treat all of humanity. But are those approvals necessary if the treatment is for me, based on my genetics, etc.? The risk, both economically and physiologically, is drastically lower.
This kind of care looks more complicated now — “ there’s no way doctors can keep track of individual plans like that” — but enables far better outcomes.
https://x.com/iterintellectus/status/2032858964858228817
0 reply
0 recast
2 reactions